Answers are grounded in this paper and cite their sources.
The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
No takes yet. Share an insight, caveat, or question.
Peter S. Dragovich (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: